Organon's Hu­mi­ra biosim­i­lar gets ex­clu­sive spot on VA for­mu­la­ry

Ab­b­Vie’s Hu­mi­ra is get­ting swapped out for Organon’s biosim­i­lar Hadli­ma on the US De­part­ment of Vet­er­ans Af­fairs’ na­tion­al for­mu­la­ry.

The move marks a big win for Organon as the drug from Mer­ck’s women’s health spin­off com­petes with eight oth­er biosim­i­lars for a share of Hu­mi­ra’s in­flam­ma­to­ry dis­ease mar­ket. Hadli­ma could be the on­ly biosim­i­lar on the VA’s for­mu­la­ry for the next five years, ac­cord­ing to the terms of the con­tract.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER